<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'>
<creators>
<creator>
<creatorName>Secrieru, I.P.</creatorName>
<affiliation>Institutul de Matematică şi Informatică "Vladimir Andrunachievici", Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Ţurcan, S.I.</creatorName>
<affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Guţuleac, E.N.</creatorName>
<affiliation>Institutul de Matematică şi Informatică "Vladimir Andrunachievici", Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Popcova, O.V.</creatorName>
<affiliation>Institutul de Matematică şi Informatică "Vladimir Andrunachievici", Moldova, Republica</affiliation>
</creator>
</creators>
<titles>
<title xml:lang='en'>Concept of informational tool for MAFLD and COVID-19 severity interplay assessment</title>
</titles>
<publisher>Instrumentul Bibliometric National</publisher>
<publicationYear>2021</publicationYear>
<relatedIdentifier relatedIdentifierType='ISBN' relationType='IsPartOf'></relatedIdentifier>
<dates>
<date dateType='Issued'>2021</date>
</dates>
<resourceType resourceTypeGeneral='Text'>Conference Paper</resourceType>
<descriptions>
<description xml:lang='en' descriptionType='Abstract'><p>The earliest evidence suggested that obese patients, who often present Metabolic Associated Fatty Liver Disease (MAFLD), are even more vulnerable at severe presentation of COVID-19. On the one hand, the e&reg;ect of compromised liver function, as a result of MAFLD, on the severity of COVID-19 illness [1] has not been well studied yet. We aim to systematize the info and data of patients with fatty liver and evaluate the severity of COVID-19 in this cohort. On the other hand, most likely, these patients will receive drugs necessary for the treatment of acute respiratory&nbsp;syndrome, antiviral agents and other drugs to treat systemic in&deg;ammation, combat bacterial and fungal superinfections. Among these pharmaceuticals can produce some drug-induced liver injury (DILI) [2]. The mechanisms of DILI are not always understood. There is a clear need for a deeper understanding of interplay between MAFLD and severity of COVID-19. For more reliable and accurate results, we plan to create a partnership and combine the e&reg;orts of medical experts and the specialists in the &macr;eld of medical informatics. The overall research objective is to elucidate relationship between fatty liver and COVID-19 by creating a data warehouse of MAFLD cases, based on a single ontology (protocol), and to provide intelligent information tool for quantifying and assessing the reciprocation of compromised liver function as a result of MAFLD and the severity of COVID-19 illness, and vice versa, COVID19 treatment and MAFLD progression, using our existing experience [3]. Relevance of the assumed overall objective is enormous, as we have witnessed the wide spread of MAFLD, which predominantly a&reg;ect people of working age, having a signi&macr;cant negative impact on social and economic development. COVID-19 pandemic only made things worse. The research for this paper have been supported by the COST Action CA17112 \Prospective European Drug-Induced Liver Injury Network&quot; and the project 20.80009.5007.22 \Intelligent information systems for solving ill-structured problems, processing knowledge and big data&quot; in the framework of the State Program.</p></description>
</descriptions>
<formats>
<format>application/pdf</format>
</formats>
</resource>